Showing results (191-200 of 648) with videos related to

Sort By:
Pageof 65
Hemasphere|June 18, 2025
Comparable outcomes for pediatric acute lymphoblastic leukemia patients receiving conditioning with total body irradiation or chemotherapy: A nationwide, Korean registry-based studyKyung Taek Hong, Jung Yoon Choi, Hyery Kim, et al.
Hemasphere|June 26, 2025
NK-type large granular lymphocyte leukemia comes of ageGianpietro Semenzato, Antonella Teramo, Gregorio Barilà, et al.
Hemasphere|December 31, 2025
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab eraAbdul-Hamid Bazarbachi, Saurabh Zanwar, Ute Hegenbart, et al.
Hemasphere|December 31, 2025
Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational studyGiovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Hemasphere|January 12, 2026
Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 studyMeral Beksac, Tulin Fıratlı Tuglular, Francesca Gay, et al.
Hemasphere|April 17, 2025
European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action based on a systematic evidence reviewFrancesca Fioredda, Michail Spanoudakis, Julia Skokowa, et al.
Hemasphere|April 4, 2025
Hepatocyte Toll-like receptors contribute to the hepcidin inflammatory response to pathogens and pathogen-derived ligandsKatharina Bonitz, Silvia Colucci, Ruiyue Qiu, et al.
Hemasphere|May 20, 2025
Metabolism in hematology: Technological advances open new perspectives on disease biology and treatmentEileen Haring, Joerg M Buescher, Petya Apostolova
Hemasphere|May 8, 2025
Integration of gene mutations in risk prognostication for watch-and-wait follicular lymphoma patients initiating first-line treatmentTian-Yuan Xu, Rong-Ji Mu, Hui-Lai Zhang, et al.
Hemasphere|May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphomaMatthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
Pageof 65